Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nigel B. Deekes"'
Autor:
Valentín Garcia-Gutiérrez, Andrija Bogdanovic, Felice Bombaci, Jelena Čugurović, Giuseppe Saglio, Jan de Jong, Šarūnas Narbutas, Peter E. Westerweel, Daniela Zackova, Antonio Almeida, Nigel B. Deekes, Giora Sharf
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 18:375-379
Treatment-free remission (TFR) after discontinuation of tyrosine kinase inhibitor therapy is now an emerging treatment goal for patients with chronic myeloid leukemia, who have achieved a deep and stable response to treatment. Although guidance is no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8bda5625d1661781bb36a23a37f89c8
https://doi.org/10.1016/j.clml.2018.04.005
https://doi.org/10.1016/j.clml.2018.04.005
Autor:
Virginia Pilipovic, Nigel B. Deekes, Cristina Constantinescu, Zack Pemberton-Whiteley, Carla Boquimpani, Naoto Takahashi, Delphine Rea, Pauline Frank, Lisa Machado, Cristina Pérez Ruiz, Joannie Clements, Sung-Ho Moon, Fabian Lang, Andrew Grigg, Merula Steagall, Jorge E. Cortes, Cornelia Borowczak
Publikováno v:
Blood. 138:4986-4986
Background A significant proportion (up to 37%) of patients (pts) with chronic phase (CP) CML experience either resistance or intolerance to first-line tyrosine kinase inhibitor (TKI) therapy within 5 years and transition to other treatment options(H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f00d458605a6cb13e39a7d07beab06c0
https://doi.org/10.1182/blood-2021-147739
https://doi.org/10.1182/blood-2021-147739
Autor:
Felice Bombaci, Nigel B. Deekes, Jennifer A. Bradley, Bahija Gouimi, Jan Geissler, Zack Pemberton-Whiteley, Rita I O Christensen, Giora Sharf, Celia Marin, Mina Daban
Publikováno v:
Leukemia
In CML, treatment-free remission (TFR) refers to having a stable deep molecular response without the need for ongoing tyrosine kinase inhibitor treatment. Whilst recommendations exist about the technical management of stopping and re-starting therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea9700ffc95a2d7dba5ded08e18dd5ab
https://pubmed.ncbi.nlm.nih.gov/32457354
https://pubmed.ncbi.nlm.nih.gov/32457354
Autor:
Andreas Hochhaus, Jan Geissler, Bahija Gouimi, Jennie Bradley, Zack Pemberton-Whiteley, Celia Marin, Nigel B. Deekes, Rita I O Christensen, Giora Sharf, Mina Daban, Felice Bombaci
Publikováno v:
Blood. 134:2934-2934
Background In Chronic Myeloid Leukemia (CML), Treatment-free Remission (TFR) refers to having a stable deep molecular response without the need for ongoing Tyrosine Kinase Inhibitor (TKI) treatment. While first recommendations exist about how to mana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::708ad6c7ca51688eeb316bc24871e60e
https://doi.org/10.1182/blood-2019-123942
https://doi.org/10.1182/blood-2019-123942